Phase 2 Prostate Cancer Trial, Recruiting NCT05851547 Sponsor: Ottawa Hospital Research Institute Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT05851547
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with prostate cancer confirmed by a tissue sample (biopsy) showing a specific type called adenocarcinoma
  • Your cancer is classified as either "unfavourable intermediate-risk" or "high-risk" localised prostate cancer (meaning it has not spread beyond the prostate area — confirm specific risk category with trial site)
  • You have had a high-powered prostate MRI scan (3 Tesla) within the last 12 months
  • You are generally able to carry out daily activities, either fully or with only minor limitations (confirm with trial site)
  • You are 18 years of age or older
  • You are willing and able to sign a consent form agreeing to take part
  • You have a planned hormone therapy treatment (called androgen deprivation therapy) using a drug called triptorelin, with or without bicalutamide — lasting up to 6 months for intermediate-risk, or up to 24 months for high-risk prostate cancer
  • All necessary tests and investigations have been completed before joining the trial

Who may not be able to join:

  • Your cancer has spread to lymph nodes in the pelvis or to other parts of the body
  • Your MRI scan results and biopsy results do not match in a specific way (confirm with trial site)
  • You have already been on hormone therapy for more than 60 days before joining
  • There are plans to treat your pelvic lymph nodes with radiotherapy as part of your care
  • You have had another cancer in the past three years (with some exceptions for certain minor skin cancers or low-grade bladder conditions — confirm with trial site)
  • You have previously had radiotherapy to the pelvis
  • You have a medical reason why you cannot receive radiotherapy to the pelvis (confirm with trial site)
  • You have ever had inflammatory bowel disease at any point in your life
  • You have had one or both hips replaced (hip replacement surgery)
  • You have had a surgical procedure on your prostate called a TURP within 6 months of your planned start date for radiotherapy
  • You are currently taking part in another clinical trial for prostate cancer treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Scott C Morgan, MD, MSc, The Ottawa Hospital Cancer Centre

Phone: 613-737-7700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Ottawa Hospital Research Institute
Registry
ClinicalTrials.gov
Start date
23 November 2023
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Genitourinary and gastrointestinal toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov